Key Professional Analysts at Canaccord Genuity Reconfirmed their ‘”Buy”’ rating for Sage Therapeutics (NASDAQ:SAGE) Shares Today. Their TP is Set to $220

June 13, 2018 - By Darren Young

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Investors sentiment increased to 1.73 in Q1 2018. Its up 0.24, from 1.49 in 2017Q4. It increased, as 22 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 47 funds opened positions while 88 raised stakes. 45.19 million shares or 9.02% more from 41.45 million shares in 2017Q4 were reported.

Royal Natl Bank Of Canada invested in 2,629 shares or 0% of the stock. Btg Pactual Global Asset Mngmt Limited accumulated 3,573 shares. Smith Asset Mgmt Limited Partnership holds 0.02% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 4,460 shares. Emerald Mutual Fund Advisers Trust holds 126,626 shares or 0.8% of its portfolio. Prudential has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). 6.87M are held by Fmr. Bnp Paribas Arbitrage holds 9,698 shares or 0% of its portfolio. Wellington Mngmt Ltd Liability Partnership owns 2.27M shares. Illinois-based Envestnet Asset Management Inc has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). State Of Wisconsin Board reported 43,000 shares stake. Tocqueville Asset Mngmt Limited Partnership has 56,355 shares. Fred Alger Incorporated holds 0.01% or 19,184 shares in its portfolio. Credit Suisse Ag reported 52,400 shares stake. Omega reported 46,700 shares. Barclays Public Limited Com holds 0% or 9,997 shares in its portfolio.

Since December 14, 2017, it had 0 insider buys, and 5 sales for $32.85 million activity. $9.57M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares were sold by Robichaud Albert. FRATES JAMES M had sold 7,000 shares worth $1.08M. On Monday, April 23 IGUCHI KIMI sold $4.02M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 28,153 shares. STARR KEVIN P sold $9.96M worth of stock or 59,000 shares. PAUL STEVEN M sold $10.00 million worth of stock or 58,139 shares.

Sage Therapeutics (NASDAQ:SAGE) Rating Reaffirmed

Recently, In an analyst report sent to investors on Wednesday, 13 June, Sage Therapeutics (NASDAQ:SAGE) shares have had their “Buy” Rating restate by research professionals at Canaccord Genuity, who currently has a $220 target price on firm. This target by Canaccord Genuity would indicate the possibile upside of 27.92 % from the close price.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 7 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SAGE Therapeutics has $277.0 highest and $20300 lowest target. $224.71’s average target is 30.66% above currents $171.98 stock price. SAGE Therapeutics had 8 analyst reports since January 31, 2018 according to SRatingsIntel. BMO Capital Markets maintained the shares of SAGE in report on Wednesday, January 31 with “Buy” rating. The firm earned “Buy” rating on Tuesday, May 22 by Chardan Capital Markets. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, February 22. SunTrust maintained the shares of SAGE in report on Tuesday, February 27 with “Buy” rating. Canaccord Genuity maintained the stock with “Buy” rating in Monday, March 26 report. BMO Capital Markets maintained the shares of SAGE in report on Monday, April 23 with “Buy” rating.

The stock decreased 2.15% or $3.78 during the last trading session, reaching $171.98. About 149,766 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 127.92% since June 13, 2017 and is uptrending. It has outperformed by 115.35% the S&P500.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on August, 2. They expect $-1.87 earnings per share, up 0.53 % or $0.01 from last year’s $-1.88 per share. After $-1.68 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.31 % negative EPS growth.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $8.00 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Businesswire.com which released: “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on June 04, 2018, also Marketwatch.com with their article: “Dow slips as Fed takes center stage, with stocks putting in mixed performance” published on June 12, 2018, Benzinga.com published: “10 Biggest Price Target Changes For Wednesday” on June 13, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Businesswire.com and their article: “Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression …” published on June 12, 2018 as well as Benzinga.com‘s news article titled: “Analyst: Sage Therapeutics Holds A Breakthrough In Depression Treatment” with publication date: June 06, 2018.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: